Subscribe to our Newsletters !!

    Business

    New Particle Analysis module introduced by Renishaw

    The module simplifies the inVia microscope so that it can identify particles on pictures and then analyse them using Raman spectroscopy. Renishaw’s inVia Raman system has a high quality microscope that’s great for producing optical images of particles on surfaces. These images are utilized to direct Raman spectroscopy measurements that quickly give chemically specific, high

    Unilever says its mouthwash will decrease 99.9% Covid in the wake of flushing

    International FMCG major Unilever on November 21 said it will bring to India its mouthwash formulation, which, it claims, will reduce 99.9 percent of coronavirus after 30 minutes of rinsing. “Unilever has confirmed that preliminary lab test results reveal that mouthwash formulation containing CPC Technology reduces 99.9 percent of SARS-CoV-2, the virus which causes COVID-19,

    Strides Pharma Science arm gets USFDA gesture for HIV treatment drug

    Drug firm Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has obtained approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate pills, used to treat HIV. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Truvada tablets of Gilead Sciences. Strides Pharma

    Viveo Health Partners with Doceree and Credihealth to Strengthen its Network in India

    Mumbai, 22nd January, 2021: Within a month of setting its footprint in the Indian market, Estonia based global e-health innovator company Viveo Health, today announced two major partnerships with the Indian companies “Doceree” and “Credihealth”. Trusted by thousands of health professionals in over 40 countries around the world, Viveo Health is committed to provide world-class

    SignalChem Enters a Clinical Trial Collaboration with Merck to Evaluate the Effect of SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

    VANCOUVER, BRITISH COLUMBIA – March 25, 2021 – Life Science Newswire – SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, announces a collaboration with Merck, known as MSD outside of the United States and Canada, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with

    Cipla enters into a licensing agreement with MSD to expand access to investigational oral therapeutic drug for COVID-19 treatment

    Mumbai, India; April 28, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has signed a non-exclusive licensing agreement with MSD a tradename of Merck & Co., Inc. Kenilworth, NJ., USA for the manufacturing and distribution of Molnupiravir, the investigational oral antiviral drug currently being studied

    Cipla Enters into a Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India

    Mumbai, India, May 10, 2021: Cipla Limited (BSE: 500087 | NSE: CIPLA EQ, hereafter referred to as “Cipla”) today announced it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval

    Lonza Launches Next Generation 4D-Nucleofector Cell Transfection Platform with Proven Performance and Enhanced Ease of Use

    Basel, Switzerland, 18 May 2021 – Lonza has launched the next generation of its popular Nucleofector® Platform. For more than 20 years, Nucleofector® Technology has led the market as the most effective non-viral cell transfection method, which can be used even for hard-to-transfect cells, such as primary cells and pluripotent stem cells. Now, with an

    Cipla launches ‘ViraGen’ a polymerase chain reaction (Covid-19 RT-PCR) test

    Mumbai, India; May 20 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd. ViraGen is Cipla’s third offering in the Covid-19 testing segment. Cipla already has partnerships

    Indica Labs and Ibex Partner to Deliver AI-powered Clinical Workflows for Digital Pathology

    ALBUQUERQUE, NM and TEL AVIV, Israel – May 20, 2021 – Life Science Newswire – Indica Labs, an industry leader in quantitative digital pathology & image management solutions, and Ibex Medical Analytics, a pioneer in artificial intelligence (AI) based cancer diagnostics, announced an agreement to integrate the Galen™ AI-based cancer diagnostics platform into the HALO